PCSK9 inhibitors and incidence of arrhythmias in clinical practice: a phase IV multicentric study

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: PCSK9 inhibitors (PCSK9i) are a novel drug class indicated for the treatment of dyslipidaemia. PCSK9i have been shown to remarkably reduce cardiovascular events in patients at high risk, but little data is currently available regar...

Descripción completa

Detalles Bibliográficos
Autores principales: Stronati, G, Parente, E, Nazziconi, M, Brugiatelli, L, Bastianoni, G, Rago, A, Comune, A, Sfredda, S, Costamagna, M, Gironella, P, Maurizi, K, Finori, L, Dello Russo, A, Russo, V, Guerra, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
34.3.3 - Arrhythmias
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207171/
http://dx.doi.org/10.1093/europace/euad122.523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207171/
http://dx.doi.org/10.1093/europace/euad122.523

Ejemplares similares